DNA/RNA
Note: With the exception of ALOX5, all human LOX genes, including ALOX12, are clustered on the short arm of chromosome 17 within a few megabases of each other. ALOX15, which has 86% sequence homology to ALOX12, is in closest proximity (17p13.2). Since chromosome 17 is known for gene duplications, the multiple LOX genes on the same chromosome may be as a result of such duplications.
Description
According to Entrez-Gene, ALOX12 gene maps to NC_000017.9 and spans a region of 16.1 kilo bases. According to Spidey (mRNA to genomic sequence alignment tool), ALOX15 has 14 exons, the sizes being 168, 202, 82, 123, 104, 161, 144, 210, 87, 170, 122, 101, 171 and 490 bp. 
Transcription

ALOX12
mRNA NM_000697 has 2335bp. Characterization of the 5' flanking region of the human ALOX12 in epidermoid carcinoma A431 cells indicated the presence of two Sp1 recognition motifs residing at -158 to -150 bp and -123 to -114 bp which are essential for gene expression.
The proposed mechanism of action is as follows: epidermal growth factor induces MAPK activation in cells, followed by the activation of JUN/AP1. The biosynthesis of c-Jun is thereby increased. Sp1 recruits HDAC1 together with c-Jun to the gene promoter. When Sp1 is deacetylated it interacts with acetylate histone 3, following which p300 is recruited to the gene promoter leading to the enhancement of the expression of 12(S)-lipoxygenase.
Pseudogene
According to Entrez Gene the arachidonate 12-lipoxygenase pseudogene (ALOX12P2) (HGNC: 13742) is located on 17p13.1. This is the 'epidermal type' 12-LOX (e-12LO) that was cloned using a murine e-LO12 probe. Humans express this functional pseudogene in the skin and hair follicles.
Protein
Note: 12S-lipoxygenases has three isoforms, named after their site of initial identification: platelet, leukocyte and epidermis. The leukocyte-type enzyme is expressed widely, while the platelet and epidermal enzymes are present in only a relatively limited number of cell types. Owing to the similarities in their genetic location, sequence and biological activities, leukocyte 12-LOX and 15-LOX-1 are often referred to as 12/15 lipoxygenase.
Description
12-LOX protein consists of 662 amino acids, with a molecular weight of 75536 Da and contains non heme iron as a cofactor. According to the NCBI conserved domain search, the presence of a polycystin/lipoxygenase/alpha-toxin (PLAT) domain in the 12-LOX protein allows it access and enables it to catalyze enzymatic lipid peroxidation in complex biological structures via direct dioxygenation of phospholipids and cholesterol esters of biomembranes and plasma lipoproteins. The same conserved domain in 15-LOX-1 also enables it to oxidize complex lipids. Although cytosolic, both types of enzymes need this domain to access their sequestered membrane or micelle bound substrates.
Expression
The platelet type 12-LOX is expressed in the platelets and skin in humans. Based on structural and enzymatic properties, 15-LOX-1 is said to be a homolog of leukocyte type 12-LOX and are both expressed in mast cells, eosinophils, activated monocytes or dendritic cells, and bronchial epithelial cells.
Localisation
All 12-LOX isoforms have been localized to the cytoplasm. In addition, the platelet-type 12S-lipoxygenase was found in both cytosol and microsomal fractions of epidermal cells of human skin. 
Implicated in
Inflammation and cancer
Note: End product of arachidonic acid metabolism by the platelet-type 12-LOX 12(S)-Hydroxy eicosatetraenoic acid (12(S)-HETE) is shown to induce invasion, motility, and angiogenesis and protect tumour cells from apoptosis. Great many biological activities of 12(S)-HETE appear to be partly mediated by the activation of NF-kappaB. NF-kappaB is a family of five DNA binding proteins that regulate the expression of a variety of genes involved in host immune responses and inflammation. A direct relationship between platelet-type 12-LOX overexpression and NFkappaB activation is reported in prostate cancer cells.
Polymorphisms associated with diseases
Note: Aberrant arachidonic acid metabolism by 12-lipoxygenase (12-LOX) is implicated in carcinogenesis. Genetic polymorphisms 12-LOX is therefore thought to influence its function and/or expression and may modify the risk for colorectal adenoma. One of the single nucleotide polymorphisms (SNPs) reported in the 12-LOX gene located in exon 6 resulting in an Arg to Gln substitution at amino acid 261 of 12-LOX is in a highly conserved region of the lipoxygenase domain. Data from a community-based, case-control study of incident, sporadic colorectal adenoma that included 162 cases and 211 controls have shown an inverse association between the Arg261Gln polymorphism in 12-LOX and colorectal adenoma (OR, 0.63; 95% CI, 0.40-1.00). A significant interaction also is observed between the 12-LOX polymorphism (Arg261Gln) and the use of nonsteroidal anti-inflammatory drugs. Another study argues that Gln261Arg in ALOX12 does not appear to be associated with colon cancer risk. Studies have shown higher urinary excretion of the arachidonic acid-derived metabolite 12-(S)hydroxyeicosatetraenoic acid (12(S)-HETE) in essential hypertension. For analysis of the association of polymorphisms in ALOX12 with hypertension and urinary levels of 12(S)-HETE, a study with 200 patients with essential hypertension and 166 matched controls is performed and as a result, the distribution of genotypes of the R261Q (Arg to Gln) polymorphism is found to be significantly different between patients and controls. These results indicate that a nonsynonymous polymorphism in ALOX12 is associated to essential hypertension and to urinary levels of 12(S)-HETE. Peak BMD is a major determinant of osteoporosis which is a complex disease with both genetic and environmental risk factors. In a population -and family -based association study of ALOX15 and ALOX12, SNPs distributed across the two genes are genotyped. Moderate evidence of association is found between spine BMD and six SNPs in the ALOX12 gene in both men and women. These data conclude that polymorphisms in the ALOX12 gene may contribute to normal variation in spine BMD.
Alzheimer's disease
Note: Alzheimer's disease (AD) is a chronic neurodegenerative disorder that impairs cognition and behavior. Although the initiating molecular events are not known, increasing evidence suggests that 12/15-LOX is a major source of oxidative stress which could play a functional role in pathogenesis. Quantitative Western blot analysis confirmed by immunohistochemical studies demonstrate that in affected frontal and temporal regions of AD brains, the amount of 12/15-LOX is higher compared to controls. Also metabolic products of 12/15-LOX are markedly elevated in AD brains compared to controls.
Bladder cancer
Note: 12-LOX expression is shown to be induced in bladder cancer tissues by an immunohistochemistry analysis. Also lipoxygenase inhibitors cause marked inhibition of bladder cancer cells in a concentration and time dependent manner. Cells treated with lipoxygenase inhibitors show chromatin condensation, cellular shrinkage, small membrane bound bodies (apoptotic bodies) and cytoplasmic condensation.
Testicular cancer
Note: 12-LOX is only slightly expressed in normal testis tissues, however, 12-LOX expression is found to be significant in testicular cancer tissues by immunohistochemistry studies. Specific LOX inhibitors have also been shown to inhibit the growth of testicular cancer in cell lines.
Prostate cancer
Note: Research focusing on mechanisms of action of 12-lipoxygenase in prostate cancer cells revealed that overexpression of 12-lipoxygenase in PC-3 cells results in a 3-fold increase in VEGF protein level when compared with vector control cells and there is an increase in PI3-kinase activity in 12-LOX-transfected PC-3 cells. The expression of 12-LOX is detected to be low in benign prostatic hyperplasia and normal prostate tissues, whereas marked expression of 12-lipoxygenase is detected in prostatic intraepithelial neoplasia and prostate cancer tissues. The LOX inhibitors cause marked cellular death through apoptosis in prostate cancer cells in a concentration and time-dependent manner. Another effect of 12-LOX in prostate cancer cells is that increase in 12-LOX expression enhances the metastatic potential of human prostate cancer cells. 12-LOX transfected PC-3 cells show a significant change in cell adhesiveness, spreading, motility, and invasiveness.
Breast cancer
Note: Total cellular RNA extraction from 64 frozen tissue samples of breast carcinoma and their corresponding normal adjacent tissues is performed for expression analysis of cyclooxygenase-2 and 12-lipooxygenase using RT-PCR. 62.5% of carcinoma samples showed over-expression of 12-lipooxygenase as compared to normal breast tissues. Results also reveal that and 12-lipooxygenase mRNA expressions are associated with TNM staging in human breast cancer. A second study indicates that levels of 12-lipoxygenases together with 5-lipoxygenase are also particularly high in tumours from patients who died of breast cancer. Therefore raised level of 12-lipoxygenase might have prognostic value in patients with breast cancer.
